N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
N/A N=144 VasQ External Support for Arteriovenous Fistula
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=10 Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique
Arteriovenous Fistula, Cannulation
Primary: Infiltration Due to Dialysis Access Cannulation — 5; 7 infiltration events
Phase 3 N=54 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
End Stage Renal Disease · AV Fistula · Kidney Failure
Primary: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis — 49 participants
N/A N=14 Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis
Renal Failure
Primary: Feasibility of Participant Recruitment and Site Coordination — 8; 6 Participants
N/A N=31 Handgrip Exercise for Arteriovenous Fistula Maturation
Chronic Kidney Disease
Primary: Venous Diameter. — 5.78; 6.42 mm
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
N/A N=75 FLEX Vessel Prep Prior to Angioplasty in Native Arteriovenous Fistulae (AVF)
Arteriovenous Fistula Stenosis
Primary: Primary Safety Endpoint: Serious Adverse Event Rate — 0; 2.7 percentage of patients
Phase 2 N=13 Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
AV Fistula
Primary: Time to AV Fistula Functional Maturation — 169; 145 Days to functional maturation
N/A N=20 Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae
Kidney Diseases · Arteriovenous Fistula
Primary: Primary Safety Endpoint — 0 MAES within 30 days post baseline visit
N/A N=44 Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
N/A N=209 Cohort Study on A Following-up System of Native Arteriovenous Fistulae
Arteriovenous Fistulae
Primary: Number of Participants With Fistula Failure — 11; 15 Participants
N/A N=46 Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
Phase 3 N=285 Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae
Arteriovenous Fistula
Primary: Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure — 71.4; 63 Percentage of Participants — p=0.0562
Phase 3 N=269 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Complication of Renal Dialysis · End Stage Renal Disease · End Stage Kidney Disease
Primary: Fistula Suitability for Dialysis at 6 Months (FSD6) — 74; 76; 21; 43 Participants — p=0.2942
N/A N=330 IN.PACT™ AV Access IDE Study
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
Phase 3 N=311 A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
Chronic Kidney Disease
Primary: Time to AVF Primary Unassisted Patency — 214; 171 Days — p=0.254
N/A N=749 Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults
Anesthesia
Primary: First Attempt Success Rate With 3 Different Technique — 132; 101; 96 participants
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
N/A N=280 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001
Phase 3 N=613 A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Chronic Kidney Disease
Primary: Kaplan-Meier Estimate of Secondary AVF Patency — NA; NA Days — p=0.932
N/A N=110 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
Phase 2 N=64 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…
N/A N=100 Technique for Successful Ultrasound-guided Peripheral Vascular Access
Obesity · Vascular Diseases
Primary: Successful First Attempt Peripheral Venous Cannulation — 96 participants
N/A N=1,004 Femoral Arterial Access With Ultrasound Trial
Vascular Access Complications · Cardiac Catheterization · Peripheral Vascular Disease
Primary: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography — 408; 431 participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…